Remagine Labs Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 10

Remagine Labs General Information

Description

Developer of wearable drug delivery systems designed for epilepsy treatment. The company's system offers a non-invasive and controlled method of delivering epilepsy medication, reducing the risk of missed doses and side effects, enabling patients to manage their condition more effectively, improving quality of life, and reducing the economic burden associated with epilepsy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Austin, TX
  • United States
+1 (512)
Primary Industry
Therapeutic Devices
Other Industries
Monitoring Equipment
Vertical(s)
Corporate Office
  • Austin, TX
  • United States
+1 (512)

Remagine Labs Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Remagine Labs Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 16-Sep-2026 Completed Generating Revenue
4. Later Stage VC 01-Jul-2025 Completed Startup
3. Grant 01-Jul-2024 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Grant $3M Completed Startup
To view Remagine Labs’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Remagine Labs Patents

Remagine Labs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025111664-A1 Transdermal drug delivery compositions Inactive 30-Nov-2023
US-20260306827-A1 Iontophoresis pharmaceutical delivery system Pending 25-May-2023
WO-2024239072-A1 Iontophoresis pharmaceutical delivery system Inactive 25-May-2023 A61N1/325

Remagine Labs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Remagine Labs Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Monash Investment Holdings University Minority
Praxis (Drug Discovery) Corporation Minority
Breakthrough Victoria Venture Capital Minority
Genesis Pre-Seed Fund Venture Capital Minority
Monash University University Minority
You’re viewing 5 of 10 investors. Get the full list »

Remagine Labs FAQs

  • When was Remagine Labs founded?

    Remagine Labs was founded in 2001.

  • Where is Remagine Labs headquartered?

    Remagine Labs is headquartered in Austin, TX.

  • What is the size of Remagine Labs?

    Remagine Labs has 7 total employees.

  • What industry is Remagine Labs in?

    Remagine Labs’s primary industry is Therapeutic Devices.

  • Is Remagine Labs a private or public company?

    Remagine Labs is a Private company.

  • What is Remagine Labs’s current revenue?

    The current revenue for Remagine Labs is .

  • How much funding has Remagine Labs raised over time?

    Remagine Labs has raised $500K.

  • Who are Remagine Labs’s investors?

    Monash Investment Holdings, Praxis (Drug Discovery), Breakthrough Victoria, Genesis Pre-Seed Fund, and Monash University are 5 of 10 investors who have invested in Remagine Labs.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process